You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Johnson and Johnson
Merck
AstraZeneca
Colorcon

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 7,947,272

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,947,272
Title:Compositions and methods of tolerizing a primate to an antigen
Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.
Inventor(s): Frewin; Mark (Oxford, GB), Waldmann; Herman (Oxford, GB), Gorman; Scott (Whitney, GB), Hale; Geoff (Marston, GB), Rao; Patricia (Acton, MA), Kornaga; Tadeusz (Cambridge, MA), Ringler; Douglas (Boston, MA), Cobbold; Stephen (Witney, GB), Winsor-Hines; Dawn (Framingham, MA)
Assignee: Tolerx, Inc. (Cambridge, MA) Isis Innovation, Ltd. (Oxford, GB) Cambridge University Technical Services, Ltd. (Cambridge, GB)
Application Number:11/486,293
Patent Claims:see list of patent claims

Details for Patent 7,947,272

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Tolerx, Inc. (Cambridge, MA) Isis Innovation, Ltd. (Oxford, GB) Cambridge University Technical Services, Ltd. (Cambridge, GB) 2021-06-14 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Tolerx, Inc. (Cambridge, MA) Isis Innovation, Ltd. (Oxford, GB) Cambridge University Technical Services, Ltd. (Cambridge, GB) 2021-06-14 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Tolerx, Inc. (Cambridge, MA) Isis Innovation, Ltd. (Oxford, GB) Cambridge University Technical Services, Ltd. (Cambridge, GB) 2021-06-14 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Tolerx, Inc. (Cambridge, MA) Isis Innovation, Ltd. (Oxford, GB) Cambridge University Technical Services, Ltd. (Cambridge, GB) 2021-06-14 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Moodys
McKinsey
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.